Plerixafor (PLER), a reversible antagonist of the CXC chemokine receptor type 4, has been
in clinical use for mobilization of blood grafts for autologous hematopoietic cell …

Aim The combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor is one
of the approaches for hematopoietic stem cell mobilization in patients with multiple myeloma …

Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells
(HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with …

Background: The main goal of this post hoc analysis of the Collaboration to Collect
Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate …

Simple Summary Herein, we retrospectively analyze in our single-center study real-life data
of 357 myeloma and lymphoma patients mobilized with granulocyte colony-stimulating factor …

Background Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous
stem cell transplantation (auto‐SCT). Study Design and Methods This prospective …

Abstract Background and Objectives Autologous stem cell transplant (ASCT) is a widely
used therapy for lymphoma patients and can nowadays be performed on an outpatient …

Autologous stem cell transplantation (auto-SCT) is an established treatment option in
patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect …

Background Adequate hematopoietic stem cell dose is required to proceed with autologous
stem cell transplantation (ASCT). Patients and Methods We conducted a retrospective …

Background aims Before autologous stem cell transplantation (ASCT), hematopoietic stem
cells must be stimulated to move from the bone marrow to the peripheral blood for …